SEC Form 4 · accession 0001104659-15-029743
MARINUS PHARMACEUTICALS INC · MRNS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gail M Farfel
Officer — Chief Clinical Dev & Reg Offic
Period of report
Apr 21, 2015
Accepted (ET)
Apr 23, 2015 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001267813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 21, 2015 | M | 30,000 | $1.04 | A | 30,000 | D | |
| Common StockF1 | Apr 21, 2015 | S | 30,000 | $9.4837 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock option (right to buy)F2 | $1.04 | Apr 21, 2015 | M | 30,000 | D | — | Apr 1, 2020 | Common Stock | 30,000 | 8,462 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 15, 2015. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.34 to $9.53, inclusive. The reporting person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
- F225% vested on 4/1/11; remaining shares vested in equal installments at the end of each of the 36 months after 4/1/11.